The positive interim data from the Phase 1 trial indicates that the treatment for advanced melanoma and metastatic non-small cell lung cancer is showing promising results. This news is directly related to Portage Biotech's core business and is likely to boost investor confidence in the company's potential, leading to a short-term increase in its stock price.